PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19885233-0 2008 Use of continuous glucose monitoring to estimate insulin requirements in patients with type 1 diabetes mellitus during a short course of prednisone. Prednisone 137-147 insulin Homo sapiens 49-56 20199368-5 2010 The homeostasis model assessment of insulin sensitivity showed intermediate values for patients who underwent a simultaneous pancreas-kidney transplant and correlated with prednisone dosages (in those who underwent kidney transplant alone) and tacrolimus levels (in patients who underwent a simultaneous pancreas-kidney transplant). Prednisone 172-182 insulin Homo sapiens 36-43 18351394-2 2008 She became overtly diabetic while receiving alternate-day prednisone and tacrolimus, requiring insulin injections. Prednisone 58-68 insulin Homo sapiens 95-102 20497628-0 2010 Effects of low or medium-dose of prednisone on insulin resistance in patients with systemic lupus erythematosus. Prednisone 33-43 insulin Homo sapiens 47-54 20497628-8 2010 Prednisone dose correlated with the HOMA index and insulin but not with inflammatory parameters (erythrocyte sedimentation rate p=0.075) after adjusting for confounder. Prednisone 0-10 insulin Homo sapiens 51-58 20497628-9 2010 CONCLUSIONS: Daily medium-dose prednisone use (>7.5 mg/d) but not low-dose (< or =7.5 mg/d) use increased insulin levels and IR in SLE, which may contribute to increased CV risk experienced by these patients. Prednisone 31-41 insulin Homo sapiens 112-119 19738036-0 2009 Short-term prednisone use antagonizes insulin"s anabolic effect on muscle protein and glucose metabolism in young healthy people. Prednisone 11-21 insulin Homo sapiens 38-45 19738036-2 2009 The purpose of this study was to test a hypothesis that prednisone (Pred) counteracts insulin"s anabolic effects on muscle. Prednisone 56-66 insulin Homo sapiens 86-93 19885233-9 2008 CONCLUSIONS: For adults with T1DM, insulin requirements during prednisone induced insulin resistance may need to be increased by 70% or more to normalize blood glucose levels. Prednisone 63-73 insulin Homo sapiens 35-42 19885233-9 2008 CONCLUSIONS: For adults with T1DM, insulin requirements during prednisone induced insulin resistance may need to be increased by 70% or more to normalize blood glucose levels. Prednisone 63-73 insulin Homo sapiens 82-89 15959811-4 2005 Based on anecdotal reports in literature, prednisone therapy was started in order to increase insulin resistance, reduce glucose utilization, increase hepatic glucose production, and impair insulin secretion. Prednisone 42-52 insulin Homo sapiens 94-101 18026162-13 2007 After the patient was treated with prednisone (60 mg/day), her insulin requirements decreased within 1 week to pre-admission doses. Prednisone 35-45 insulin Homo sapiens 63-70 18026162-16 2007 On a maintenance dose of 10 mg prednisone/day, glucose control improved (HbA(1c) 5.8%) with an average of 60 U of isophane insulin twice daily. Prednisone 31-41 insulin Homo sapiens 123-130 8549855-1 1996 Hyperinsulinemia and peripheral insulin resistance caused by systemic insulin delivery and prednisone therapy are recognized consequences of pancreas transplantation. Prednisone 91-101 insulin Homo sapiens 5-12 10360582-15 1999 Patients receiving prednisone tended to have greater biochemical signs of cholestasis, higher serum cholesterol and glucose levels, and more frequent insulin requirement than those treated without corticosteroids. Prednisone 19-29 insulin Homo sapiens 150-157 9467587-9 1998 Insulin antibody levels decreased and [123I]insulin biodistribution improved after treatment with plasmapheresis and prednisone. Prednisone 117-127 insulin Homo sapiens 0-7 9467587-9 1998 Insulin antibody levels decreased and [123I]insulin biodistribution improved after treatment with plasmapheresis and prednisone. Prednisone 117-127 insulin Homo sapiens 44-51 9371526-2 1997 Serum insulin and plasma glucose levels in 18 newly diagnosed cases and 11 previously treated cases with prednisone were significantly higher than those in the controls. Prednisone 105-115 insulin Homo sapiens 6-13 9259593-10 1997 Fasting insulin and C-peptide levels were increased up to 6 mo after transplantation, indicating insulin resistance partially induced by prednisone. Prednisone 137-147 insulin Homo sapiens 8-15 9229189-5 1997 The allergic symptoms disappeared only after treatment with short acting human insulin (up to 100 U/day) associated to prednisone-40 mg/day and cetirizine dihydrochloride for 4 months. Prednisone 119-129 insulin Homo sapiens 79-86 9229189-6 1997 However, after stopping prednisone the urticaria reappeared and it was relieved with insulin desensitization. Prednisone 24-34 insulin Homo sapiens 85-92 9178026-6 1997 Basal levels of SI and FPIR were found to be independent predictors of change in insulin sensitivity and together explained 83% of the change in insulin sensitivity produced by short term treatment with prednisone. Prednisone 203-213 insulin Homo sapiens 81-88 9178026-6 1997 Basal levels of SI and FPIR were found to be independent predictors of change in insulin sensitivity and together explained 83% of the change in insulin sensitivity produced by short term treatment with prednisone. Prednisone 203-213 insulin Homo sapiens 145-152 14730612-9 2004 Prednisone dosage explained only 15.6% of the variance in insulin levels. Prednisone 0-10 insulin Homo sapiens 58-65 9934814-5 1998 The patients reporting symptoms were less likely to be insulin resistant with longer time post-PTX, lower body mass index (BMI), and on lower doses of prednisone. Prednisone 151-161 insulin Homo sapiens 55-62 9829612-9 1998 Two patients treated with prednisone or octreotide had insulin levels similar to those of normal TPN children. Prednisone 26-36 insulin Homo sapiens 55-62 2015969-1 1991 Human growth hormone (hGH) and prednisone cause insulin resistance and glucose intolerance. Prednisone 31-41 insulin Homo sapiens 48-55 7973537-0 1994 [The effect of long-term cyclosporin and prednisone therapy on insulin secretory reserve]. Prednisone 41-51 insulin Homo sapiens 63-70 7973537-1 1994 Insulin secretory reserve assessed by the method of glucose potentiation of arginine induced insulin secretion is decreased in non-diabetic transplant recipients using triple immunosuppressive therapy with prednisone, cyclosporine, and azathioprine. Prednisone 206-216 insulin Homo sapiens 0-7 8344127-6 1993 Insulin antibodies (IA) were significantly lower in the prednisone group at second and third month (P < 0.05). Prednisone 56-66 insulin Homo sapiens 0-7 8344127-7 1993 No patient experienced complete remission but in 10 prednisone and 4 control patients the insulin requirements were below 0.3 IU/kg (P < 0.05). Prednisone 52-62 insulin Homo sapiens 90-97 8344127-9 1993 The profile of the insulin requirements during the follow-up was different in the two groups and at 9 months the prednisone group needed less insulin than the control (P < 0.05). Prednisone 113-123 insulin Homo sapiens 19-26 8344127-9 1993 The profile of the insulin requirements during the follow-up was different in the two groups and at 9 months the prednisone group needed less insulin than the control (P < 0.05). Prednisone 113-123 insulin Homo sapiens 142-149 1644247-9 1992 We conclude that, despite prednisone-induced insulin resistance, normal glucose tolerance is achieved by hyperinsulinaemia and normalisation of glucose-dependent glucose disposal following pancreas-kidney transplantation in Type 1 diabetic patients. Prednisone 26-36 insulin Homo sapiens 45-52 1897023-11 1991 The indirect evidence of insulin resistance observed in patients treated with CsA plus prednisone is ascribable to corticosteroid treatment. Prednisone 87-97 insulin Homo sapiens 25-32 2019924-4 1991 The integrated insulin concentration correlated directly with the prednisone dose on day 1 of an alternate-day regimen (R2 = 0.355) and with age (partial R2 = 0.163). Prednisone 66-76 insulin Homo sapiens 15-22 1820114-6 1991 Prednisone can be withdrawn from almost all patients with no rejection by 1 year with significant improvement in blood pressure, daily insulin requirement in diabetics, total blood cholesterol, and low density lipoproteins (LDL). Prednisone 0-10 insulin Homo sapiens 135-142 8472623-5 1993 Introduction of combined immunosuppressive therapy (prednisone plus azathioprine) together with plasmapheresis resulted in rapid lowering of daily insulin requirement and reduction in anti-insulin antibodies. Prednisone 52-62 insulin Homo sapiens 147-154 8472623-5 1993 Introduction of combined immunosuppressive therapy (prednisone plus azathioprine) together with plasmapheresis resulted in rapid lowering of daily insulin requirement and reduction in anti-insulin antibodies. Prednisone 52-62 insulin Homo sapiens 189-196 8472623-6 1993 Immunosuppressive therapy was continued with 10 mg of prednisone and a year later the patients insulin daily requirement was 0.66 U/kg BW while his antibodies were 18%. Prednisone 54-64 insulin Homo sapiens 95-102 8300055-4 1993 We have recently demonstrated that high-dose rhGH together with prednisone prevents the protein-catabolic effects observed with treatment with prednisone alone, while inducing insulin resistance and increased secretion of proinsulin. Prednisone 64-74 insulin Homo sapiens 176-183 8300055-4 1993 We have recently demonstrated that high-dose rhGH together with prednisone prevents the protein-catabolic effects observed with treatment with prednisone alone, while inducing insulin resistance and increased secretion of proinsulin. Prednisone 64-74 insulin Homo sapiens 222-232 2015969-6 1991 Plasma insulin concentrations were elevated during therapy with prednisone alone and rhGH alone (667 +/- 72 and 564 +/- 65 pmol/ml, respectively, P less than 0.001) compared with placebo (226 +/- 44 pmol/ml) but lower than with the combined rhGH and prednisone treatment (1249 +/- 54 pmol/ml, P less than 0.01). Prednisone 64-74 insulin Homo sapiens 7-14 2015969-6 1991 Plasma insulin concentrations were elevated during therapy with prednisone alone and rhGH alone (667 +/- 72 and 564 +/- 65 pmol/ml, respectively, P less than 0.001) compared with placebo (226 +/- 44 pmol/ml) but lower than with the combined rhGH and prednisone treatment (1249 +/- 54 pmol/ml, P less than 0.01). Prednisone 250-260 insulin Homo sapiens 7-14 2252527-6 1990 A lower insulin requirement was observed in the prednisone group than in other patients at 12 months (0.33 +/- 0.11 vs 0.57 +/- 0.06 U/kg/day, P less than 0.05), 18 months (0.34 +/- 0.11 vs 0.64 +/- 0.06, P less than 0.05) and 24 months (0.38 +/- 0.10 vs 0.63 +/- 0.05, P less than 0.05). Prednisone 48-58 insulin Homo sapiens 8-15 2252527-7 1990 Endogenous insulin release, evaluated as urinary C-peptide, was higher in the prednisone group than in other patients at 3, 6, 9, 12, 18 and 24 months (P less than 0.05). Prednisone 78-88 insulin Homo sapiens 11-18 2252527-9 1990 Our study indicates that prednisone administration, at low doses and for a long period of time, effectively restored endogenous insulin release in IDDM patients. Prednisone 25-35 insulin Homo sapiens 128-135 2253832-7 1990 The insulin-stimulated peripheral glucose uptake was reduced in the prednisone-treated group, but normal in cyclosporin-treated subjects. Prednisone 68-78 insulin Homo sapiens 4-11 6355186-0 1983 An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. Prednisone 50-60 insulin Homo sapiens 69-76 2088967-5 1990 CsA, azathioprine and prednisone all appear to have the potential for adverse effects variously on islet engraftment, insulin secretion, and/or peripheral insulin activity. Prednisone 22-32 insulin Homo sapiens 118-125 2088967-5 1990 CsA, azathioprine and prednisone all appear to have the potential for adverse effects variously on islet engraftment, insulin secretion, and/or peripheral insulin activity. Prednisone 22-32 insulin Homo sapiens 155-162 2642487-5 1989 After the patient had received immunosuppressive therapy with prednisone and cyclophosphamide for 3 months, her insulin resistance remitted, and she developed hypoglycemia. Prednisone 62-72 insulin Homo sapiens 112-119 3827456-7 1987 Also, insulin requirement was significantly lower after deflazacort than after prednisone (29.3 +/- 11.6 vs 47.3 +/- 2.0 U/d). Prednisone 79-89 insulin Homo sapiens 6-13 2596599-3 1989 In the postabsorptive state prednisone therapy increased (P less than 0.05) plasma concentrations of leucine, alpha-ketoisocaproate, glucose, insulin, and C-peptide, as well as leucine carbon flux and oxidation calculated by means of isotope dilution techniques and [1-13C]leucine. Prednisone 28-38 insulin Homo sapiens 110-164 2571541-0 1989 Contribution of insulin resistance to catabolic effect of prednisone on leucine metabolism in humans. Prednisone 58-68 insulin Homo sapiens 16-23 2655543-5 1989 Fasting plasma glucose levels were not modified by deflazacort, whereas fasting plasma glucose levels together with insulin and C-peptide values were progressively and significantly increased by prednisone and betamethasone. Prednisone 195-205 insulin Homo sapiens 116-123 6355186-4 1983 The insulin sensitivity index (glucose metabolic clearance rate in ml/kg per min) was significantly lower (P less than 0.001) after prednisone at all three steady state plasma insulin levels: 2.8 +/- 0.3 vs. 7.4 +/- 1.1 at approximately 100 microU/ml; 6.0 +/- 0.5 vs. 12.2 +/- 1.1 at approximately 1,000 microU/ml; 7.4 +/- 0.6 vs. 14.4 +/- 0.5 at approximately 10,000 microU/ml. Prednisone 132-142 insulin Homo sapiens 176-183 6355186-6 1983 Suppression of glucose production at steady state plasma insulin level of approximately 100 microU/ml was less after prednisone (1.01 +/- 0.35 vs. 0.14 +/- 0.13, NS), and total at approximately 1,000 and approximately 10,000 microU/ml after both prednisone and placebo. Prednisone 117-127 insulin Homo sapiens 57-64 6355186-1 1983 Prednisone-induced insulin resistance may depend on either reduced sensitivity (receptor defect) or reduced response to insulin (postreceptor defect). Prednisone 0-10 insulin Homo sapiens 19-26 6355186-7 1983 The metabolic kinetic parameters of insulin after prednisone were not significantly different from those after placebo. Prednisone 50-60 insulin Homo sapiens 36-43 6355186-1 1983 Prednisone-induced insulin resistance may depend on either reduced sensitivity (receptor defect) or reduced response to insulin (postreceptor defect). Prednisone 0-10 insulin Homo sapiens 120-127 6355186-10 1983 These results suggest that (a) administration of an anti-inflammatory dose of prednisone for 7 d induces insulin resistance in man; (b) this is more dependent on depressed peripheral glucose utilization than on increased endogenous production; (c) total insulin binding on isolated adipocytes is not significantly affected; (d) insulin resistance is primarily the outcome of postreceptor defect (impaired glucose transport). Prednisone 78-88 insulin Homo sapiens 105-112 6355186-10 1983 These results suggest that (a) administration of an anti-inflammatory dose of prednisone for 7 d induces insulin resistance in man; (b) this is more dependent on depressed peripheral glucose utilization than on increased endogenous production; (c) total insulin binding on isolated adipocytes is not significantly affected; (d) insulin resistance is primarily the outcome of postreceptor defect (impaired glucose transport). Prednisone 78-88 insulin Homo sapiens 254-261 6355186-10 1983 These results suggest that (a) administration of an anti-inflammatory dose of prednisone for 7 d induces insulin resistance in man; (b) this is more dependent on depressed peripheral glucose utilization than on increased endogenous production; (c) total insulin binding on isolated adipocytes is not significantly affected; (d) insulin resistance is primarily the outcome of postreceptor defect (impaired glucose transport). Prednisone 78-88 insulin Homo sapiens 254-261 6355186-2 1983 To clarify the mechanism of prednisone-induced insulin resistance, a [3H]glucose infusion (1 microCi/min) was performed for 120 min before and during a euglycemic clamp repeated at approximately 100, approximately 1,000, and approximately 10,000 microU/ml steady state plasma insulin concentration in 10 healthy, normal weight subjects, aged 35 +/- 7 yr. Each test was repeated after 7-d administration of placebo or prednisone (15 plus 15 mg/d per subject), in a randomized sequence with an interval of 1 mo between the two tests. Prednisone 28-38 insulin Homo sapiens 47-54 6749880-0 1982 Hypercortisolism and insulin resistance: comparative effects of prednisone, hydrocortisone, and dexamethasone on insulin binding of human erythrocytes. Prednisone 64-74 insulin Homo sapiens 113-120 6341389-1 1983 We measured [125I]insulin binding to circulating monocytes or erythrocytes from 16 patients with chronic glucocorticoid excess, 9 chronically treated with prednisone and 7 with adrenocortical hyperfunction. Prednisone 155-165 insulin Homo sapiens 18-25 6336620-3 1983 Normal subjects were studied to determine the effects of diet and oral prednisone on urinary C-peptide excretion. Prednisone 71-81 insulin Homo sapiens 93-102 6336620-5 1983 When insulin production is increased after oral prednisone, there is also a positive correlation with body mass index and percent ideal body weight. Prednisone 49-59 insulin Homo sapiens 5-12 6336620-6 1983 Prednisone increases plasma glucose, immunoreactive insulin, and serum and urinary C-peptide levels beginning 8-12 h after oral administration. Prednisone 0-10 insulin Homo sapiens 52-59 6336620-6 1983 Prednisone increases plasma glucose, immunoreactive insulin, and serum and urinary C-peptide levels beginning 8-12 h after oral administration. Prednisone 0-10 insulin Homo sapiens 83-92 6749880-8 1982 Prednisone ingestion caused significant insulin resistance with an insignificant decrease in insulin binding. Prednisone 0-10 insulin Homo sapiens 40-47 6749880-6 1982 We conclude that although hydrocortisone, dexamethasone, and prednisone all cause deterioration of glucose tolerance and decreased insulin sensitivity, only hydrocortisone and dexamethasone exhibit significant decreases in insulin binding to erythrocytes. Prednisone 61-71 insulin Homo sapiens 131-138 7014590-5 1981 When prednisone (40 mg/day) was given to normal subjects for 3 days, a moderate state of insulin resistance was induced characterized by a modest increase in blood glucose and a more pronounced increase in plasma insulin concentration. Prednisone 5-15 insulin Homo sapiens 89-96 7014590-5 1981 When prednisone (40 mg/day) was given to normal subjects for 3 days, a moderate state of insulin resistance was induced characterized by a modest increase in blood glucose and a more pronounced increase in plasma insulin concentration. Prednisone 5-15 insulin Homo sapiens 213-220 7002662-0 1980 Decreased insulin binding of human erythrocytes after dexamethasone or prednisone ingestion. Prednisone 71-81 insulin Homo sapiens 10-17 7002662-1 1980 We have investigated changes in insulin binding in erythrocytes in response to overnight ingestion of 1 mg dexamethasone or 10 mg of prednisone in two groups of eight lean, healthy subjects. Prednisone 133-143 insulin Homo sapiens 32-39 7002662-3 1980 Prednisone ingestion reduced insulin binding from 9.9 to 7.9% (P < 0.01), but the increase in basal insulin from 16.9 to 20.6 microU/ml was not significantly different. Prednisone 0-10 insulin Homo sapiens 29-36 7002662-4 1980 The decrease in insulin binding with both dexamethasone and prednisone was associated with decreased affinity of erythrocyte for insulin at low occupancy and the increase in the dose of unlabeled insulin resulted in 50% inhibition of specific binding without changes in the number of receptors. Prednisone 60-70 insulin Homo sapiens 16-23 7002662-4 1980 The decrease in insulin binding with both dexamethasone and prednisone was associated with decreased affinity of erythrocyte for insulin at low occupancy and the increase in the dose of unlabeled insulin resulted in 50% inhibition of specific binding without changes in the number of receptors. Prednisone 60-70 insulin Homo sapiens 129-136 7002662-4 1980 The decrease in insulin binding with both dexamethasone and prednisone was associated with decreased affinity of erythrocyte for insulin at low occupancy and the increase in the dose of unlabeled insulin resulted in 50% inhibition of specific binding without changes in the number of receptors. Prednisone 60-70 insulin Homo sapiens 129-136 5078362-0 1972 [Effect of prednisone on variations in the immunoreactive insulin blood level after intravenous injection of glucose in children]. Prednisone 11-21 insulin Homo sapiens 58-65 6997328-1 1980 Results of a recent study suggested that depending upon the glucocorticoid or the model used, opposite changes occur in insulin binding; in fact, the increase in insulin receptor number on monocytes after prednisone ingestion in man appears to contrast with previous reports in animals in which a decrease was shown after dexamethasone. Prednisone 205-215 insulin Homo sapiens 120-127 373474-2 1979 In those patients receiving 100 mg or more of prednisone per day and 5 per cent dextrose solution, the hourly infusion rate was determined from tthe following equation: insulin (U) = plasma glucose value divided by 100. Prednisone 46-56 insulin Homo sapiens 169-176 1159064-10 1975 Thus, prednisone apparently has an early inhibitory effect on the insulin response to glucose. Prednisone 6-16 insulin Homo sapiens 66-73 1263838-0 1976 Free and total insulin levels in a patient with insulin-resistant diabetes mellitus and chronic lymphatic leukemia: effect of prednisone therapy. Prednisone 126-136 insulin Homo sapiens 15-22 1263838-2 1976 In response to prednisone therapy, his insulin requirement decreased, but the total and free insulin concentrations increased as insulin antibody measured as the maximal insulin-binding capacity of plasma remained unchanged. Prednisone 15-25 insulin Homo sapiens 39-46 1263838-2 1976 In response to prednisone therapy, his insulin requirement decreased, but the total and free insulin concentrations increased as insulin antibody measured as the maximal insulin-binding capacity of plasma remained unchanged. Prednisone 15-25 insulin Homo sapiens 93-100 1263838-2 1976 In response to prednisone therapy, his insulin requirement decreased, but the total and free insulin concentrations increased as insulin antibody measured as the maximal insulin-binding capacity of plasma remained unchanged. Prednisone 15-25 insulin Homo sapiens 93-100 1263838-2 1976 In response to prednisone therapy, his insulin requirement decreased, but the total and free insulin concentrations increased as insulin antibody measured as the maximal insulin-binding capacity of plasma remained unchanged. Prednisone 15-25 insulin Homo sapiens 93-100 1263838-4 1976 The beneficial effect of prednisone treatment in this patient is discussed, and it is postulated to be the result of either increased availability of free insulin or an increased responsiveness of the tissues to insulin or both. Prednisone 25-35 insulin Homo sapiens 155-162 1263838-4 1976 The beneficial effect of prednisone treatment in this patient is discussed, and it is postulated to be the result of either increased availability of free insulin or an increased responsiveness of the tissues to insulin or both. Prednisone 25-35 insulin Homo sapiens 212-219 32369480-2 2020 This study aims to compare the impact on beta-cell function and insulin resistance of prednisone 40 mg between adults with newly diagnosed T2DM and healthy adults. Prednisone 86-96 insulin Homo sapiens 64-71 4186346-0 1969 The effect of alternating prednisone therapy on insulin binding. Prednisone 26-36 insulin Homo sapiens 48-55 22145998-0 2011 Relapsing insulin-induced lipoatrophy, cured by prolonged low-dose oral prednisone: a case report. Prednisone 72-82 insulin Homo sapiens 10-17 24961832-6 2014 The first episode of insulin-induced localized involutional lipoatrophy two years previously had been cured by oral prednisone. Prednisone 116-126 insulin Homo sapiens 21-28 27882163-4 2016 After treating with prednisone for 2 months, his insulin level started decreasing. Prednisone 20-30 insulin Homo sapiens 49-56 25675382-3 2015 We report the successful treatment of a patient with type B insulin resistance with rituximab, cyclophosphamide, and prednisone. Prednisone 117-127 insulin Homo sapiens 60-67 22180452-8 2012 Oral glucose tolerance tests revealed significant increases in glycaemic excursion on days 1 and 7, whereas increases in insulin and C-peptide excursions were more notable on day 7 with all doses of prednisone. Prednisone 199-209 insulin Homo sapiens 121-128 21635675-2 2011 METHODS: The objective of this study was to quantify the effects of daily 10 or 25 mg prednisone administration for one week on insulin sensitivity by employing a two-step hyperinsulinemic euglycemic glucose clamp (Step 1: insulin infusion = 20 mU/m2/min; Step 2: insulin infusion = 80 mU/m2/min) in healthy, lean males. Prednisone 86-96 insulin Homo sapiens 128-135 21635675-7 2011 The insulin sensitivity index, Si, calculated as the quotient of augmentation of M/I between Step 1 and 2, was reduced by 35.3% (p < 0.01) and 23.5% (p < 0.05) for 25 and 10 mg prednisone, respectively. Prednisone 183-193 insulin Homo sapiens 4-11